Vertex Pharmaceuticals Incorporated Company Profile (NASDAQ:VRTX)

About Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Therapeutic Drugs
Sub-Industry: Biotechnology
Symbol: NASDAQ:VRTX
CUSIP: 92532F10
Web: www.vrtx.com

Capitalization:

Market Cap: $38.9 billion
Outstanding Shares: 249,068,000

Average Prices:

50 Day Moving Avg: $134.32
200 Day Moving Avg: $109.69
52 Week Range: $71.46 - $167.00

P/E:

Trailing P/E Ratio: 227.92
Foreward P/E Ratio: 49.12
P/E Growth: 1.48

Sales & Book Value:

Annual Revenue: $2.02 billion
Price / Sales: 19.26
Book Value: $6.03 per share
Price / Book: 25.90

Profitability:

EBIDTA: $356.32 million
Net Margins: 8.64%
Return on Equity: 3.00%
Return on Assets: 1.47%

Debt:

Debt-to-Equity Ratio: 0.02%
Current Ratio: 3.82%
Quick Ratio: 3.65%

Misc:

Average Volume: 2.11 million shs.
Beta: 1.74
Short Ratio: 1.89

Frequently Asked Questions for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

What is Vertex Pharmaceuticals Incorporated's stock symbol?

Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."

How were Vertex Pharmaceuticals Incorporated's earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its quarterly earnings data on Wednesday, July, 26th. The company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.33. The business earned $544.10 million during the quarter, compared to the consensus estimate of $489.95 million. Vertex Pharmaceuticals Incorporated had a net margin of 8.64% and a return on equity of 3.00%. The company's revenue for the quarter was up 26.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.24 EPS. View Vertex Pharmaceuticals Incorporated's Earnings History.

When will Vertex Pharmaceuticals Incorporated make its next earnings announcement?

Vertex Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Monday, October, 23rd 2017. View Earnings Estimates for Vertex Pharmaceuticals Incorporated.

Where is Vertex Pharmaceuticals Incorporated's stock going? Where will Vertex Pharmaceuticals Incorporated's stock price be in 2017?

24 brokerages have issued 1-year price objectives for Vertex Pharmaceuticals Incorporated's stock. Their predictions range from $81.00 to $200.00. On average, they expect Vertex Pharmaceuticals Incorporated's share price to reach $158.68 in the next year. View Analyst Ratings for Vertex Pharmaceuticals Incorporated.

What are analysts saying about Vertex Pharmaceuticals Incorporated stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:

1. According to Zacks Investment Research, "Vertex has two CF drugs – Kalydeco & Orkambi – in its portfolio with blockbuster potential. Its efforts to get the drugs approved for additional indications are encouraging. Label expansion will increase the patient population and boost sales. Vertex’s CF pipeline is quite strong with a broad portfolio of next-generation CF correctors. Investor focus will now be on the triple combination CF regimens, which are crucial for long-term growth at Vertex. Multiple triple combo data readouts in CF patients are expected in 2H17. The stock has also done well this year. However, Vertex has faced many challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles and a slower-than-anticipated uptake in Germany. Estimates have also gone up slightly ahead of the company’s Q2 earnings release. The company has a positive record of earnings surprises in recent quarters." (7/4/2017)
2. Needham & Company LLC analysts commented, "Vertex announced 1Q17 financial results last night. Orkambi WW sales $295M beat our $277.5M and consensus $280M ests. Kalydeco WW sales $186M beat our $178.0M and consensus $175M ests. Mgmt raised Kalydeco, but left unch Orkambi guidance ($1.1-1.3B Orkambi and $710M-$730M from $690-710M Kalydeco). Orkambi driven by strong uptake and compliance in pediatric pts and Kalydeco driven by one time reimbursement in Europe. Our 2Q17 Orkambi and Kalydeco ests are $294.0M (was $287.5M) and $179.0M (was $178.0M). Stock reflects IVA/ TEZ commercial success and we maintain HOLD." (4/28/2017)
3. Maxim Group analysts commented, "Vertex reported 1Q17 with total CF revenue of $481M, which was above consensus of $444M, driven by both Orkambi and Kalydeco revenues beating estimates." (4/28/2017)
4. BMO Capital Markets analysts commented, "We believe Vertex's acquisition of Concert's CTP-656, a deuterated ivacaftor (Kalydeco), removes a key potential competitor in the cystic fibrosis space. In addition, CTP-656 could replace Kalydeco in the triple combo, allowing a once-daily (QD) regimen, which would offset an important advaVertex Pharma (NASDAQ: VRTX)ntage of Galapagos's QD triple combo in development. We also believe CTP-656's later patent expiration date (2032 vs. 2027 for Kalydeco) will be an important lifecycle management component of Vertex's cystic fibrosis franchise." (3/7/2017)
5. Robert W. Baird analysts commented, "Vertex announced plans to acquire Concert Pharmaceuticals' CTP-656, or deuterated ivacaftor. We think this acquisition highlights Vertex's commitment to defending its position as the leading CF company as it both eliminates a potential competitor and allows access to a once-daily modified version of ivacaftor with a longer patent life than ivacaftor itself. Overall, we think this is a smart deal for the company at a reasonable price, and reiterate our Outperform rating." (3/6/2017)

Who are some of Vertex Pharmaceuticals Incorporated's key competitors?

Some companies that are related to Vertex Pharmaceuticals Incorporated include Regeneron Pharmaceuticals (REGN), Exelixis (EXEL), BIOVERATIV INC (BIVV), TESARO (TSRO), Kite Pharma (KITE), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), China Biologic Products (CBPO), AveXis (AVXS), Prothena Corporation PLC (PRTA) and Axovant Sciences (AXON).

Who are Vertex Pharmaceuticals Incorporated's key executives?

Vertex Pharmaceuticals Incorporated's management team includes the folowing people:

Jeffrey M. Leiden M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
Ian F. Smith CPA, Chief Financial Officer, Chief Operating Officer, Executive Vice President
Michael J. Parini J.D., Executive Vice President, Chief Legal and Administrative Officer
David Altshuler M.D., Ph.D., Executive Vice President - Global Research, Chief Scientific Officer
Stuart A. Arbuckle, Executive Vice President, Chief Commercial Officer
Jeffrey A. Chodakewitz M.D., Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Amit K. Sachdev J.D., Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
Paul M. Silva, Senior Vice President, Corporate Controller
Bruce I. Sachs, Lead Director, Independent Director
Elaine S. Ullian, Co-Lead Independent Director

Who owns Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Manning & Napier Advisors LLC (0.65%), Public Employees Retirement Association of Colorado (0.21%), Strs Ohio (0.14%), AMF Pensionsforsakring AB (0.13%), Atalanta Sosnoff Capital LLC (0.12%) and Chevy Chase Trust Holdings Inc. (0.10%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Elaine Ullian, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee. View Institutional Ownership Trends for Vertex Pharmaceuticals Incorporated.

Who sold Vertex Pharmaceuticals Incorporated stock? Who is selling Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, APG Asset Management N.V., Factory Mutual Insurance Co., Gateway Investment Advisers LLC, NGAM Advisors L.P., Exxonmobil Investment Management Inc. TX, Capstone Asset Management Co. and Hartford Investment Management Co.. Company insiders that have sold Vertex Pharmaceuticals Incorporated stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia and Stuart A Arbuckle. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

Who bought Vertex Pharmaceuticals Incorporated stock? Who is buying Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was acquired by a variety of institutional investors in the last quarter, including Atalanta Sosnoff Capital LLC, Acadian Asset Management LLC, Russell Investments Group Ltd., Great West Life Assurance Co. Can, Bank of Montreal Can, Spark Investment Management LLC, Mn Services Vermogensbeheer B.V. and Cullinan Associates Inc.. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

How do I buy Vertex Pharmaceuticals Incorporated stock?

Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals Incorporated's stock price today?

One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $156.19.

MarketBeat Community Rating for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		928 (Vote Outperform)
Underperform Votes:		493 (Vote Underperform)
Total Votes:		1,421

MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	3 Hold Ratings, 21 Buy Ratings
Consensus Rating:	Buy (Score: 2.88)
Consensus Price Target:	$158.68 (1.59% upside)

Analysts' Ratings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
7/27/2017	BMO Capital Markets	Reiterated Rating	Outperform	$180.00 -> $182.00	Low
7/27/2017	Oppenheimer Holdings, Inc.	Boost Price Target	Outperform	$150.00 -> $175.00	Medium
7/27/2017	J P Morgan Chase & Co	Set Price Target	Buy	$175.00 -> $184.00	High
7/27/2017	Maxim Group	Set Price Target	Buy	$195.00	High
7/22/2017	Morgan Stanley	Reiterated Rating	Overweight	$153.00 -> $190.00	Low
7/21/2017	Robert W. Baird	Reiterated Rating	Outperform	$136.00 -> $171.00	Low
7/21/2017	Needham & Company LLC	Reiterated Rating	Buy	$155.00 -> $195.00	Low
7/21/2017	Citigroup Inc.	Reiterated Rating	Buy	$135.00 -> $190.00	Low
7/19/2017	Credit Suisse Group	Boost Price Target	Outperform	$125.00 -> $195.00	High
7/19/2017	JMP Securities	Reiterated Rating	Outperform		High
7/19/2017	Raymond James Financial, Inc.	Upgrade	Market Perform -> Outperform	$181.00	High
7/19/2017	Piper Jaffray Companies	Boost Price Target	Overweight	$194.00	High
7/19/2017	Jefferies Group LLC	Reiterated Rating	Buy	$155.00 -> $185.00	High
7/19/2017	HC Wainwright	Reiterated Rating	Hold	$85.00	High
7/19/2017	Janney Montgomery Scott	Upgrade	Neutral -> Buy	$98.00	High
7/19/2017	Cowen and Company	Upgrade	Market Perform -> Outperform	$105.00 -> $200.00	High
7/19/2017	Barclays PLC	Upgrade	Equal Weight -> Overweight	$115.00 -> $180.00	High
7/18/2017	Stifel Nicolaus	Boost Price Target	Buy -> Buy	$130.00 -> $154.00	High
6/22/2017	Leerink Swann	Reiterated Rating	Outperform		Medium
6/2/2017	CIBC	Upgrade	Market Perform -> Outperform		Low
5/19/2017	Bank of America Corporation	Reiterated Rating	Neutral	$121.00 -> $125.00	Low
3/14/2017	Argus	Reiterated Rating	Buy	$115.00 -> $92.95	Low
11/1/2016	William Blair	Downgrade	Outperform -> Market Perform	$105.00 -> $81.00	N/A
10/12/2016	Royal Bank Of Canada	Reiterated Rating	Buy		N/A
4/28/2016	Goldman Sachs Group, Inc. (The)	Downgrade	Buy -> Neutral	$109.00 -> $88.00	N/A
3/28/2016	Guggenheim	Lower Price Target	Buy	$145.00 -> $114.00	N/A
9/15/2015	Nomura	Initiated Coverage	Buy	$162.00	N/A
7/31/2015	Deutsche Bank AG	Reiterated Rating	Buy	$155.00	N/A

(Data available from 7/28/2015 forward)

Earnings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Earnings by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Earnings History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/23/2017		$0.40					N/A
7/26/2017	Q2 2017	$0.06	$0.39	$489.95 million	$544.10 million	View	N/A
4/27/2017	Q1 2017	$0.04	$0.13	$692.64 million	$714.72 million	View	N/A
1/25/2017	Q4 2016	$0.29	$0.35	$453.40 million	$458.71 million	View	N/A
10/25/2016	Q316	$0.18	$0.16	$423.53 million	$413.78 million	View	Listen
7/27/2016	Q216	$0.21	$0.24	$428.08 million	$431.61 million	View	Listen
4/27/2016	Q116	$0.29	$0.09	$439.94 million	$398.10 million	View	Listen
1/27/2016	Q4	$0.17	$0.17	$406.30 million	$417.94 million	View	Listen
10/28/2015	Q315	($0.60)	($0.13)	$245.84 million	$309.82 million	View	Listen
7/29/2015	Q215	($0.58)	($0.54)	$149.49 million	$166.00 million	View	Listen
4/29/2015	Q115	($0.75)	($0.62)	$142.38 million	$138.51 million	View	Listen
1/28/2015	Q414	($0.65)	($0.55)	$137.50 million	$144.56 million	View	Listen
10/28/2014	Q314	($0.62)	($0.37)	$146.20 million	$179.00 million	View	N/A
7/29/2014	Q214	($0.71)	($0.61)	$131.85 million	$138.42 million	View	Listen
5/1/2014	Q114	($0.68)	($0.65)	$134.46 million	$118.50 million	View	N/A
1/29/2014	Q413	($0.49)	($0.56)	$221.08 million	$351.20 million	View	Listen
10/29/2013	Q413	($0.33)	($0.32)	$278.80 million	$222.00 million	View	N/A
7/29/2013	Q2 2013	($0.18)	($0.26)	$308.02 million	$310.80 million	View	N/A
4/30/2013	Q1 2013	($0.06)	$0.03	$307.85 million	$328.40 million	View	N/A
1/29/2013	Q4 2012	($0.07)	($0.35)	$318.53 million	$334.00 million	View	N/A
11/1/2012	Q312	$0.34	$0.13	$377.14 million	$336.00 million	View	N/A
7/30/2012		$0.68	$0.46			View	N/A
4/26/2012		$0.57	$0.43			View	N/A
2/2/2012		$0.76	$0.74			View	N/A
10/27/2011		$0.17	$0.70			View	N/A
7/28/2011		($1.00)	($0.67)			View	N/A
5/3/2011		($1.09)	($0.91)			View	N/A
2/3/2011		($0.93)	($0.74)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

2017 EPS Consensus Estimate: $0.60

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	4	($0.02)	$0.04	$0.02
Q2 2017	4	$0.02	$0.11	$0.07
Q3 2017	3	$0.08	$0.14	$0.10
Q4 2017	3	$0.26	$0.64	$0.41

(Data provided by Zacks Investment Research)

Dividend History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/29/2013	quarterly	$0.40			2/20/2013	3/13/2013

(Data available from 1/1/2013 forward)

Insider Trading and Institutional Ownership History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Insider Ownership Percentage: 1.80%
Institutional Ownership Percentage: 94.20%

Institutional Ownership by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
7/21/2017	Amit Sachdev	EVP	Sell	28,625	$160.93	$4,606,621.25
7/21/2017	Ian F Smith	CFO	Sell	133,750	$160.98	$21,531,075.00
7/21/2017	Jeffrey Chodakewitz	CMO	Sell	46,733	$160.96	$7,522,143.68
7/21/2017	Jeffrey M Leiden	CEO	Sell	216,624	$160.96	$34,867,799.04
7/21/2017	Paul M Silva	SVP	Sell	43,443	$161.07	$6,997,364.01
7/19/2017	Michael Parini	EVP	Sell	10,829	$161.00	$1,743,469.00
7/17/2017	Jeffrey Chodakewitz	CMO	Sell	573	$129.85	$74,404.05
7/3/2017	Jeffrey Chodakewitz	CMO	Sell	3,438	$127.80	$439,376.40
6/21/2017	Jeffrey Chodakewitz	CMO	Sell	5,157	$132.87	$685,210.59
6/21/2017	Paul M Silva	SVP	Sell	2,577	$133.36	$343,668.72
6/5/2017	David Altshuler	EVP	Sell	7,500	$130.00	$975,000.00
6/2/2017	Jeffrey M Leiden	CEO	Sell	147,101	$129.50	$19,049,579.50
6/2/2017	Sangeeta N Bhatia	Director	Sell	1,176	$128.44	$151,045.44
6/2/2017	Stuart A Arbuckle	EVP	Sell	70,969	$128.06	$9,088,290.14
5/2/2017	Jeffrey Chodakewitz	CMO	Sell	8,979	$121.05	$1,086,907.95
4/28/2017	Jeffrey M Leiden	CEO	Sell	157,200	$119.50	$18,785,400.00
4/5/2017	Jeffrey Chodakewitz	CMO	Sell	8,021	$114.00	$914,394.00
4/3/2017	Jeffrey Chodakewitz	CMO	Sell	2,291	$108.85	$249,375.35
3/29/2017	Amit Sachdev	EVP	Sell	80,500	$107.63	$8,664,215.00
3/29/2017	Jeffrey Chodakewitz	CMO	Sell	13,750	$106.65	$1,466,437.50
3/29/2017	Paul M Silva	SVP	Sell	1,688	$106.30	$179,434.40
1/11/2017	Joshua S Boger	Director	Sell	8,000	$82.48	$659,840.00
1/4/2017	Joshua S Boger	Director	Sell	6,500	$77.13	$501,345.00
12/29/2016	Joshua S Boger	Director	Sell	6,500	$74.33	$483,145.00
12/21/2016	Joshua S Boger	Director	Sell	6,500	$74.16	$482,040.00
12/14/2016	Joshua S Boger	Director	Sell	6,500	$77.52	$503,880.00
11/30/2016	Joshua S Boger	Director	Sell	6,500	$83.48	$542,620.00
11/23/2016	Joshua S Boger	Director	Sell	6,500	$86.47	$562,055.00
11/16/2016	Joshua S Boger	Director	Sell	6,500	$91.55	$595,075.00
11/10/2016	Paul M Silva	SVP	Sell	5,062	$90.98	$460,540.76
11/9/2016	Joshua S Boger	Director	Sell	6,500	$90.98	$591,370.00
11/9/2016	Stuart A Arbuckle	EVP	Sell	1,208	$90.00	$108,720.00
11/2/2016	Joshua S Boger	Director	Sell	6,500	$77.75	$505,375.00
10/26/2016	Joshua S Boger	Director	Sell	6,500	$79.26	$515,190.00
10/19/2016	Joshua S Boger	Director	Sell	6,500	$81.84	$531,960.00
10/12/2016	Joshua S Boger	Director	Sell	6,500	$81.14	$527,410.00
10/5/2016	Joshua S Boger	Director	Sell	6,500	$87.44	$568,360.00
10/3/2016	Stuart A Arbuckle	EVP	Sell	1,208	$86.46	$104,443.68
9/28/2016	Joshua S Boger	Director	Sell	6,500	$88.15	$572,975.00
9/21/2016	Joshua S Boger	Director	Sell	6,500	$90.82	$590,330.00
9/14/2016	Joshua S Boger	Director	Sell	6,500	$92.37	$600,405.00
9/7/2016	Joshua S Boger	Director	Sell	6,500	$95.66	$621,790.00
8/31/2016	Joshua S Boger	Director	Sell	6,500	$94.62	$615,030.00
8/24/2016	Joshua S Boger	Director	Sell	7,500	$100.46	$753,450.00
8/22/2016	Joshua S Boger	Director	Sell	1,100	$100.79	$110,869.00
8/17/2016	Joshua S Boger	Director	Sell	6,900	$99.63	$687,447.00
8/11/2016	Joshua S Boger	Director	Sell	900	$100.19	$90,171.00
8/10/2016	Joshua S Boger	Director	Sell	7,100	$100.24	$711,704.00
8/3/2016	Joshua S Boger	Director	Sell	47,000	$100.66	$4,731,020.00
7/27/2016	Joshua S Boger	Director	Sell	6,500	$95.93	$623,545.00
7/20/2016	Joshua S Boger	Director	Sell	6,500	$90.33	$587,145.00
7/13/2016	Joshua S Boger	Director	Sell	6,500	$88.81	$577,265.00
7/6/2016	Joshua S Boger	Director	Sell	5,140	$88.99	$457,408.60
6/29/2016	Joshua S Boger	Director	Sell	5,130	$84.82	$435,126.60
6/22/2016	Joshua S Boger	Director	Sell	5,130	$86.61	$444,309.30
6/15/2016	Joshua S Boger	Director	Sell	5,130	$91.18	$467,753.40
6/8/2016	Joshua S Boger	Director	Sell	5,130	$94.95	$487,093.50
6/1/2016	Joshua S Boger	Director	Sell	5,130	$93.65	$480,424.50
5/25/2016	Joshua S Boger	Director	Sell	5,130	$89.09	$457,031.70
5/18/2016	Joshua S Boger	Director	Sell	5,130	$81.18	$416,453.40
5/16/2016	Amit Sachdev	EVP	Sell	117	$81.67	$9,555.39
5/16/2016	Ian F Smith	CFO	Sell	202	$82.06	$16,576.12
5/11/2016	Joshua S Boger	Director	Sell	5,130	$86.50	$443,745.00
5/9/2016	Paul M Silva	SVP	Sell	3,000	$87.63	$262,890.00
5/4/2016	Joshua S Boger	Director	Sell	5,130	$81.02	$415,632.60
4/27/2016	Joshua S Boger	Director	Sell	5,130	$83.67	$429,227.10
4/20/2016	Joshua S Boger	Director	Sell	5,130	$84.10	$431,433.00
4/13/2016	Joshua S Boger	Director	Sell	5,130	$84.27	$432,305.10
4/6/2016	Joshua S Boger	Director	Sell	5,130	$89.56	$459,442.80
3/30/2016	Joshua S Boger	Director	Sell	5,130	$78.83	$404,397.90
3/23/2016	Joshua S Boger	Director	Sell	5,130	$81.38	$417,479.40
3/16/2016	Joshua S Boger	Director	Sell	5,130	$79.65	$408,604.50
3/2/2016	Joshua S Boger	Director	Sell	5,130	$91.80	$470,934.00
2/24/2016	Joshua S Boger	Director	Sell	5,130	$85.25	$437,332.50
2/17/2016	Joshua S. Boger	Director	Sell	5,130	$86.93	$445,950.90
2/10/2016	Joshua S. Boger	Director	Sell	5,130	$82.57	$423,584.10
2/3/2016	Ian F. Smith	CFO	Sell	12,084	$90.84	$1,097,710.56
2/3/2016	Jeffrey M. Leiden	CEO	Sell	9,834	$90.82	$893,123.88
2/3/2016	Joshua S. Boger	Director	Sell	5,130	$90.81	$465,855.30
2/3/2016	Paul M. Silva	SVP	Sell	5,062	$90.82	$459,730.84
2/3/2016	Stuart A. Arbuckle	EVP	Sell	6,042	$90.82	$548,734.44
2/2/2016	Jeffrey Chodakewitz	CMO	Sell	2,375	$91.38	$217,027.50
1/27/2016	Joshua S. Boger	Director	Sell	11,200	$93.22	$1,044,064.00
1/20/2016	Joshua S. Boger	Director	Sell	10,400	$93.69	$974,376.00
1/13/2016	Joshua S. Boger	Director	Sell	10,400	$98.41	$1,023,464.00
1/6/2016	Joshua S. Boger	Director	Sell	10,400	$121.96	$1,268,384.00
1/4/2016	Yuchun Lee	Director	Sell	1,125	$122.21	$137,486.25
12/30/2015	Joshua S. Boger	Director	Sell	10,400	$127.15	$1,322,360.00
12/21/2015	Joshua S. Boger	Director	Sell	10,400	$119.26	$1,240,304.00
12/9/2015	Joshua S. Boger	Director	Sell	10,400	$120.80	$1,256,320.00
12/4/2015	Stuart A. Arbuckle	EVP	Sell	4,531	$123.98	$561,753.38
12/2/2015	Joshua S. Boger	Director	Sell	10,400	$130.91	$1,361,464.00
12/1/2015	David Altshuler	EVP	Sell	5,000	$131.00	$655,000.00
12/1/2015	Yuchun Lee	Director	Sell	1,125	$129.65	$145,856.25
11/23/2015	Joshua S. Boger	Director	Sell	10,400	$132.18	$1,374,672.00
11/11/2015	Joshua S. Boger	Director	Sell	10,400	$118.59	$1,233,336.00
11/4/2015	Joshua S. Boger	Director	Sell	10,400	$124.23	$1,291,992.00
11/2/2015	Yuchun Lee	Director	Sell	1,125	$126.19	$141,963.75
10/28/2015	Joshua S. Boger	Director	Sell	10,400	$119.01	$1,237,704.00
10/21/2015	Joshua S. Boger	Director	Sell	10,400	$108.82	$1,131,728.00
10/14/2015	Joshua S. Boger	Director	Sell	10,400	$112.62	$1,171,248.00
10/7/2015	Joshua S. Boger	Director	Sell	10,400	$109.61	$1,139,944.00
10/2/2015	Elaine Ullian	Director	Sell	20,000	$110.00	$2,200,000.00
10/1/2015	Stuart A. Arbuckle	EVP	Sell	12,417	$104.71	$1,300,184.07
10/1/2015	Yuchun Lee	Director	Sell	1,125	$104.64	$117,720.00
9/30/2015	Joshua S. Boger	Director	Sell	10,400	$103.14	$1,072,656.00
9/23/2015	Joshua S. Boger	Director	Sell	10,400	$111.89	$1,163,656.00
9/16/2015	Joshua S. Boger	Director	Sell	10,400	$133.24	$1,385,696.00
9/9/2015	Joshua S. Boger	Director	Sell	10,400	$131.41	$1,366,664.00
9/4/2015	Stuart A. Arbuckle	EVP	Sell	9,063	$125.77	$1,139,853.51
9/2/2015	Joshua S. Boger	Director	Sell	10,400	$125.85	$1,308,840.00
9/1/2015	Yuchun Lee	Director	Sell	1,125	$125.40	$141,075.00
8/26/2015	Joshua S. Boger	Director	Sell	10,400	$124.71	$1,296,984.00
8/19/2015	Joshua S. Boger	Director	Sell	10,400	$139.93	$1,455,272.00
8/12/2015	Joshua S Boger	Director	Sell	10,400	$135.83	$1,412,632.00
7/22/2015	Joshua S Boger	Director	Sell	10,400	$130.92	$1,361,568.00
7/15/2015	Joshua S Boger	Director	Sell	12,200	$133.98	$1,634,556.00
7/13/2015	Paul M Silva	SVP	Sell	1,125	$123.79	$139,263.75
7/8/2015	Joshua S Boger	Director	Sell	11,700	$122.74	$1,436,058.00
7/2/2015	Jeffrey Chodakewitz	CMO	Sell	2,291	$129.36	$296,363.76
7/1/2015	Joshua S Boger	Director	Sell	11,700	$125.60	$1,469,520.00
6/24/2015	Joshua S Boger	Director	Sell	11,700	$130.41	$1,525,797.00
6/17/2015	Joshua S Boger	Director	Sell	11,700	$123.90	$1,449,630.00
6/10/2015	Joshua S Boger	Director	Sell	11,700	$125.02	$1,462,734.00
5/20/2015	Joshua S Boger	Director	Sell	11,700	$126.73	$1,482,741.00
5/6/2015	Joshua S Boger	Director	Sell	11,700	$122.79	$1,436,643.00
5/5/2015	Paul M Silva	SVP	Sell	4,101	$123.68	$507,211.68
4/29/2015	Joshua S Boger	Director	Sell	11,700	$124.59	$1,457,703.00
4/27/2015	Paul M Silva	SVP	Sell	1,125	$129.74	$145,957.50
4/27/2015	Stuart A Arbuckle	EVP	Sell	61,480	$129.36	$7,953,052.80
4/27/2015	Terrence C Kearney	Director	Sell	68,125	$129.11	$8,795,618.75
4/22/2015	Joshua S Boger	Director	Sell	11,700	$132.46	$1,549,782.00
4/15/2015	Joshua S Boger	Director	Sell	11,700	$129.25	$1,512,225.00
4/13/2015	Paul M Silva	SVP	Sell	1,125	$128.60	$144,675.00
4/8/2015	Joshua S Boger	Director	Sell	11,700	$123.26	$1,442,142.00
4/6/2015	Margaret G Mcglynn	Director	Sell	12,500	$118.36	$1,479,500.00
4/2/2015	Jeffrey Chodakewitz	CMO	Sell	2,291	$115.50	$264,610.50
4/1/2015	Joshua S Boger	Director	Sell	11,700	$115.87	$1,355,679.00
3/25/2015	Joshua S Boger	Director	Sell	11,700	$120.76	$1,412,892.00
3/23/2015	Amit Sachdev	EVP	Sell	17,083	$132.28	$2,259,739.24
3/23/2015	Ian F Smith	CFO	Sell	6,042	$125.67	$759,298.14
3/23/2015	Paul M Silva	SVP	Sell	2,250	$125.65	$282,712.50
3/18/2015	Amit Sachdev	EVP	Sell	12,000	$130.00	$1,560,000.00
2/5/2015	Paul M Silva	SVP	Sell	1,688	$109.75	$185,258.00
2/4/2015	Joshua S Boger	Director	Sell	5,700	$108.81	$620,217.00
2/3/2015	Paul M Silva	SVP	Sell	2,063	$108.89	$224,640.07
2/2/2015	Jeffrey Chodakewitz	CMO	Sell	1,188	$109.60	$130,204.80
1/28/2015	Joshua S Boger	Director	Sell	10,688	$122.78	$1,312,272.64
1/26/2015	Paul M Silva	SVP	Sell	1,125	$125.62	$141,322.50
1/21/2015	Joshua S Boger	Director	Sell	10,500	$125.08	$1,313,340.00
1/14/2015	Joshua S Boger	Director	Sell	10,500	$120.16	$1,261,680.00
1/9/2015	Amit Sachdev	EVP	Sell	12,000	$125.00	$1,500,000.00
1/9/2015	Bruce I Sachs	Director	Sell	9,861	$125.04	$1,233,019.44
1/7/2015	Joshua S Boger	Director	Sell	10,500	$119.32	$1,252,860.00
1/2/2015	Jeffrey Chodakewitz	CMO	Sell	2,291	$122.54	$280,739.14
12/22/2014	Joshua S Boger	Director	Sell	10,500	$117.65	$1,235,325.00
12/17/2014	Joshua S Boger	Director	Sell	10,500	$110.66	$1,161,930.00
12/15/2014	Jeffrey M Leiden	CEO	Sell	50,017	$114.97	$5,750,454.49
12/12/2014	Paul M Silva	SVP	Sell	2,813	$120.08	$337,785.04
11/28/2014	Amit Sachdev	EVP	Sell	12,000	$120.00	$1,440,000.00
11/28/2014	Bruce I Sachs	Director	Sell	10,000	$120.03	$1,200,300.00
11/28/2014	Paul M Silva	SVP	Sell	8,164	$119.85	$978,455.40
11/26/2014	Joshua S Boger	Director	Sell	10,500	$114.54	$1,202,670.00
11/6/2014	Bruce I Sachs	Director	Sell	9,900	$115.21	$1,140,579.00
11/5/2014	Bruce I Sachs	Director	Sell	30,100	$112.62	$3,389,862.00
11/3/2014	Joshua S Boger	Director	Sell	127,411	$112.20	$14,295,514.20
10/29/2014	Joshua S Boger	Director	Sell	10,500	$109.44	$1,149,120.00
10/28/2014	Amit Sachdev	EVP	Sell	12,000	$115.00	$1,380,000.00
10/28/2014	David Altshuler	Director	Sell	2,000	$114.75	$229,500.00
10/28/2014	Jeffrey Chodakewitz	CMO	Sell	3,438	$115.00	$395,370.00
10/27/2014	Paul M Silva	SVP	Sell	1,125	$110.03	$123,783.75
10/13/2014	Paul M Silva	SVP	Sell	1,125	$107.89	$121,376.25
10/7/2014	Jeffrey Chodakewitz	CMO	Sell	3,436	$104.26	$358,237.36
10/6/2014	David Altshuler	Director	Sell	1,405	$109.75	$154,198.75
10/1/2014	Elaine Ullian	Director	Sell	5,000	$107.74	$538,700.00
10/1/2014	Stuart A Arbuckle	EVP	Sell	12,417	$107.71	$1,337,435.07
9/30/2014	Amit Sachdev	SVP	Sell	86,000	$112.68	$9,690,480.00
9/30/2014	Ian F Smith	CFO	Sell	108,026	$112.68	$12,172,369.68
9/30/2014	Jeffrey M Leiden	CEO	Sell	200,000	$112.69	$22,538,000.00
9/30/2014	Kenneth L Horton	EVP	Sell	36,000	$112.69	$4,056,840.00
9/29/2014	David Altshuler	Director	Sell	2,500	$114.75	$286,875.00
9/24/2014	Joshua S Boger	Director	Sell	5,200	$109.21	$567,892.00
9/19/2014	David Altshuler	Director	Sell	5,000	$102.25	$511,250.00
9/19/2014	Paul M Silva	SVP	Sell	25,408	$99.85	$2,536,988.80
9/19/2014	Stuart A Arbuckle	EVP	Sell	55,521	$100.00	$5,552,100.00
9/17/2014	Joshua S Boger	Director	Sell	5,200	$93.62	$486,824.00
9/10/2014	Joshua S Boger	Director	Sell	5,200	$94.42	$490,984.00
9/5/2014	David Altshuler	Director	Sell	2,500	$94.75	$236,875.00
9/3/2014	Joshua S Boger	Director	Sell	5,200	$92.79	$482,508.00
8/27/2014	Joshua S Boger	Director	Sell	5,200	$93.31	$485,212.00
8/20/2014	Joshua S Boger	Director	Sell	5,200	$91.51	$475,852.00
8/13/2014	Joshua S Boger	Director	Sell	5,200	$88.00	$457,600.00
8/6/2014	Joshua S Boger	Director	Sell	5,200	$86.54	$450,008.00
7/31/2014	David Altshuler	Director	Sell	5,000	$89.59	$447,950.00
7/31/2014	Paul M Silva	SVP	Sell	2,027	$88.97	$180,342.19
7/30/2014	Joshua S Boger	Director	Sell	5,200	$92.17	$479,284.00
7/15/2014	Wayne Joseph Riley	Director	Sell	4,800	$96.65	$463,920.00
7/1/2014	Elaine Ullian	Director	Sell	5,000	$95.21	$476,050.00
7/1/2014	Kenneth L Horton	EVP	Sell	30,134	$95.22	$2,869,359.48
6/24/2014	Megan E Pace	SVP	Sell	12,734	$98.03	$1,248,314.02
6/24/2014	Wayne Joseph Riley	Director	Sell	15,000	$98.03	$1,470,450.00
6/16/2014	Peter Mueller	EVP	Sell	7,500	$68.31	$512,325.00
6/9/2014	Elaine Ullian	Director	Sell	2,500	$75.00	$187,500.00
5/14/2014	Peter Mueller	EVP	Sell	7,500	$67.45	$505,875.00
5/2/2014	Megan Pace	SVP	Sell	1,000	$67.62	$67,620.00
4/15/2014	Peter Mueller	EVP	Sell	7,500	$61.63	$462,225.00
4/9/2014	Elaine Ullian	Director	Sell	2,500	$70.00	$175,000.00
3/21/2014	Bruce Sachs	Director	Sell	8,700	$74.59	$648,933.00
3/17/2014	Peter Mueller	EVP	Sell	7,500	$78.29	$587,175.00
2/7/2014	Jeffrey Leiden	CEO	Sell	35,944	$80.00	$2,875,520.00
1/22/2014	Bruce Sachs	Director	Sell	8,300	$84.47	$701,101.00
1/21/2014	Megan Pace	SVP	Sell	1,250	$85.00	$106,250.00
1/16/2014	Jeffrey Leiden	CEO	Sell	45,000	$80.00	$3,600,000.00
1/15/2014	Peter Mueller	EVP	Sell	7,500	$78.67	$590,025.00
12/23/2013	Bruce Sachs	Director	Sell	8,300	$73.02	$606,066.00
12/16/2013	Peter Mueller	EVP	Sell	7,500	$64.69	$485,175.00
12/12/2013	Jeffrey Leiden	CEO	Sell	9,834	$65.48	$643,930.32
12/12/2013	Kenneth Horton	EVP	Sell	4,532	$65.46	$296,664.72
12/12/2013	Megan Pace	SVP	Sell	5,083	$65.48	$332,834.84
12/4/2013	Joshua Boger	Director	Sell	1,400	$67.48	$94,472.00
11/25/2013	Joshua Boger	Director	Sell	1,400	$66.89	$93,646.00
11/20/2013	Bruce Sachs	Director	Sell	8,300	$65.28	$541,824.00
11/19/2013	Joshua Boger	Director	Sell	1,400	$62.31	$87,234.00
11/5/2013	Joshua Boger	Director	Sell	1,400	$65.64	$91,896.00
10/29/2013	Joshua S Boger	Director	Sell	1,400	$75.42	$105,588.00
10/29/2013	Thomas Connolly	SVP	Sell	1,688	$75.04	$126,667.52
10/24/2013	Bruce I Sachs	Director	Sell	8,300	$77.06	$639,598.00
10/23/2013	Joshua S Boger	Director	Sell	1,400	$76.77	$107,478.00
10/16/2013	Joshua S Boger	Director	Sell	1,400	$75.41	$105,574.00
10/15/2013	Peter Mueller	EVP	Sell	7,500	$73.25	$549,375.00
10/14/2013	Paul Silva	SVP	Sell	1,593	$71.87	$114,488.91
10/9/2013	Joshua Boger	Director	Sell	1,400	$72.35	$101,290.00
9/25/2013	Joshua Boger	Director	Sell	1,400	$74.72	$104,608.00
9/18/2013	Joshua Boger	Director	Sell	1,400	$77.43	$108,402.00
9/16/2013	Peter Mueller	EVP	Sell	7,500	$77.22	$579,150.00
9/11/2013	Joshua Boger	Director	Sell	1,400	$79.61	$111,454.00
9/4/2013	Joshua Boger	Director	Sell	1,400	$75.45	$105,630.00
8/29/2013	Bruce Sachs	Director	Sell	8,300	$77.19	$640,677.00
8/28/2013	Joshua Boger	Director	Sell	1,400	$76.24	$106,736.00
8/21/2013	Joshua Boger	Director	Sell	1,400	$76.96	$107,744.00
8/15/2013	Peter Mueller	EVP	Sell	7,500	$77.41	$580,575.00
8/14/2013	Joshua Boger	Director	Sell	1,400	$77.18	$108,052.00
8/7/2013	Joshua Boger	Director	Sell	1,400	$77.84	$108,976.00
8/5/2013	Paul Silva	SVP	Sell	3,001	$78.90	$236,778.90
7/31/2013	Joshua S Boger	Director	Sell	1,400	$80.89	$113,246.00
7/29/2013	Wayne Joseph Riley	Director	Sell	9,800	$80.09	$784,882.00
7/25/2013	Paul M Silva	SVP	Sell	1,125	$86.49	$97,301.25
7/24/2013	Bruce I Sachs	Director	Sell	8,300	$85.50	$709,650.00
7/19/2013	Amit Sachdev	SVP	Sell	22,250	$88.69	$1,973,352.50
7/18/2013	Joshua S Boger	Director	Sell	1,400	$86.12	$120,568.00
7/16/2013	Paul M Silva	SVP	Sell	2,063	$86.25	$177,933.75
7/15/2013	Christiana Stamoulis	SVP	Sell	1,125	$86.35	$97,143.75
7/15/2013	Peter Mueller	EVP	Sell	7,500	$86.34	$647,550.00
7/12/2013	Megan E Pace	SVP	Sell	10,678	$85.00	$907,630.00
7/11/2013	Joshua S Boger	Director	Sell	1,400	$83.83	$117,362.00
7/8/2013	Kenneth L Horton	EVP	Sell	1,813	$80.72	$146,345.36
7/8/2013	Megan E Pace	SVP	Sell	28,703	$80.89	$2,321,785.67
7/5/2013	Christiana Stamoulis	SVP	Sell	4,687	$81.21	$380,631.27
7/3/2013	Joshua S Boger	Director	Sell	1,400	$80.20	$112,280.00
7/2/2013	Peter Mueller	EVP	Sell	122,300	$79.80	$9,759,540.00
6/26/2013	Joshua S Boger	Director	Sell	1,400	$78.59	$110,026.00
6/21/2013	Bruce I Sachs	Director	Sell	8,300	$75.93	$630,219.00
6/19/2013	Joshua S Boger	Director	Sell	1,400	$79.11	$110,754.00
6/12/2013	Joshua S Boger	Director	Sell	1,400	$81.19	$113,666.00
6/5/2013	Joshua S Boger	Director	Sell	1,400	$77.15	$108,010.00
5/30/2013	Joshua S Boger	Director	Sell	1,400	$82.47	$115,458.00
5/22/2013	Joshua S Boger	Director	Sell	1,400	$79.72	$111,608.00
5/15/2013	Joshua S Boger	Director	Sell	1,400	$79.36	$111,104.00
5/14/2013	Bruce I Sachs	Director	Sell	60,000	$81.15	$4,869,000.00
12/26/2012	Joshua S Boger	Director	Sell	4,000	$41.86	$167,440.00
11/7/2012	Margaret G Mcglynn	Director	Buy	1,000	$45.50	$45,500.00
10/8/2012	Ian F Smith	CFO	Sell	44,787	$60.00	$2,687,220.00
10/3/2012	Joshua S Boger	Director	Sell	4,000	$57.74	$230,960.00
9/5/2012	Joshua S Boger	Director	Sell	4,000	$54.70	$218,800.00

(Data available from 1/1/2013 forward)

Headline Trends for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Latest Headlines for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Source:

Date	Headline
	BMO Capital Markets Reaffirms Outperform Rating for Vertex Pharmaceuticals Incorporated (VRTX) www.americanbankingnews.com - July 27 at 10:27 PM
	Vertex Pharmaceuticals Incorporated (VRTX) Price Target Raised to $175.00 www.americanbankingnews.com - July 27 at 1:14 PM
	Earnings Reaction History: Vertex Pharmaceuticals Incorporated, 40.0% Follow-Through Indicator, 2.6% Sensitive - Nasdaq www.nasdaq.com - July 27 at 9:19 AM
	Vertex Pharmaceuticals’ Focus on Innovative Combination Regimens finance.yahoo.com - July 27 at 9:19 AM
	Investor Network: Vertex Pharmaceuticals Incorporated to Host Earnings Call finance.yahoo.com - July 27 at 9:19 AM
	Vertex Reports Second-Quarter 2017 Financial Results finance.yahoo.com - July 27 at 9:19 AM
	Vertex Pharma reports quarterly profit finance.yahoo.com - July 27 at 9:19 AM
	Vertex Pharma's quarterly profit beats estimates finance.yahoo.com - July 27 at 9:18 AM
	Vertex Sinks Late Despite Crushing Sales, Profit Expectations finance.yahoo.com - July 27 at 9:18 AM
	Vertex tops Street 2Q forecasts finance.yahoo.com - July 27 at 9:18 AM
	Edited Transcript of VRTX earnings conference call or presentation 26-Jul-17 9:15pm GMT finance.yahoo.com - July 27 at 9:18 AM
	Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Posts Earnings Results www.americanbankingnews.com - July 26 at 9:14 PM
	Vertex Pharma (VRTX), Concert Pharmaceuticals (CNCE) Complete Asset Purchase Agreement for CTP-656 - StreetInsider.com www.streetinsider.com - July 26 at 9:50 AM
	Why Vertex Pharmaceuticals (VRTX) Might Surprise This Earnings Season - Nasdaq www.nasdaq.com - July 26 at 9:50 AM
	Gilead Faces 6th Quarter of Falling Revenue finance.yahoo.com - July 26 at 9:50 AM
	Vertex Pharmaceuticals: Robust Growth Trends for Kalydeco in 2017 finance.yahoo.com - July 26 at 9:50 AM
	Why Vertex Pharmaceuticals Could Expand Its Addressable Market finance.yahoo.com - July 26 at 9:50 AM
	Why Vertex Pharmaceuticals (VRTX) Might Surprise This Earnings Season www.zacks.com - July 25 at 8:20 AM
	Vertex Energy, Inc. to Release Second Quarter 2017 Financial Results on August 8, 2017 finance.yahoo.com - July 25 at 8:19 AM
	JMP Securities Reiterates Outperform Rating for Vertex Pharmaceuticals Incorporated (VRTX) www.americanbankingnews.com - July 24 at 12:28 AM
	Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given a $195.00 Price Target by Maxim Group Analysts www.americanbankingnews.com - July 23 at 3:49 PM
	Vertex Pharmaceuticals Incorporated (VRTX) Given a $175.00 Price Target by J P Morgan Chase & Co Analysts www.americanbankingnews.com - July 23 at 3:49 PM
	Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings? finance.yahoo.com - July 23 at 9:34 AM
	Morgan Stanley Reiterates Overweight Rating for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) www.americanbankingnews.com - July 22 at 9:32 AM
	Jeffrey M. Leiden Sells 216,624 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock www.americanbankingnews.com - July 22 at 7:23 AM
	Ian F. Smith Sells 133,750 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock www.americanbankingnews.com - July 22 at 7:23 AM
	Michael Parini Sells 10,829 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock www.americanbankingnews.com - July 22 at 7:22 AM
	Paul M. Silva Sells 43,443 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock www.americanbankingnews.com - July 22 at 7:22 AM
	Vertex Pharmaceuticals Incorporated (VRTX) EVP Amit Sachdev Sells 28,625 Shares www.americanbankingnews.com - July 22 at 7:22 AM
	Vertex Pharmaceuticals Incorporated (VRTX) CMO Jeffrey Chodakewitz Sells 46,733 Shares www.americanbankingnews.com - July 22 at 7:22 AM
	Vertex Pharmaceuticals Incorporated (VRTX) Receives Outperform Rating from Robert W. Baird www.americanbankingnews.com - July 21 at 1:44 PM
	Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Earns Buy Rating from Needham & Company LLC www.americanbankingnews.com - July 21 at 1:44 PM
	Vertex Pharmaceuticals' (VRTX) "Outperform" Rating Reaffirmed at BMO Capital Markets www.americanbankingnews.com - July 21 at 12:31 PM
	Citigroup Inc. Reaffirms Buy Rating for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) www.americanbankingnews.com - July 21 at 12:30 PM
	Q3 2017 EPS Estimates for Vertex Pharmaceuticals Incorporated Reduced by Leerink Swann (NASDAQ:VRTX) www.americanbankingnews.com - July 21 at 9:04 AM
	Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock Like Its 20% Gain Never Happened investorplace.com - July 20 at 10:03 AM
	Vertex (VRTX) Triple Combination CF Studies Data Positive www.zacks.com - July 19 at 9:24 PM
	Vertex Pharmaceuticals Inc. (VRTX) Is Surging To A New High On Study Results www.rttnews.com - July 19 at 9:24 PM
	Vertex Pharmaceuticals (VRTX) Phase 1 And 2 Data For Triple Combination Regimens Demonstrate Improvements In Lung Function And Other Measures In CF Pa seekingalpha.com - July 19 at 9:24 PM
	Maxim Hikes Price Targets on 2 Biotech Stocks: AEterna Zentaris Inc. (USA) (AEZS), Vertex Pharmaceuticals Incorporated (VRTX) finance.yahoo.com - July 19 at 9:24 PM
	Vertex Pharmaceuticals Stock Is Soaring: Here's Why It's Still Not Too Late to Buy finance.yahoo.com - July 19 at 9:24 PM
	GLOBAL MARKETS-World stocks tally 9th day of gains as earnings pick up finance.yahoo.com - July 19 at 9:24 PM
	[$$] Vertex Shares Haven’t Hit Their Apex finance.yahoo.com - July 19 at 9:24 PM
	Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells $74,404.05 in Stock www.americanbankingnews.com - July 19 at 8:01 PM
	Mid-Morning Market Update: Markets Rise; Morgan Stanley Beats Q2 Estimates - Benzinga www.benzinga.com - July 19 at 4:20 PM
	Mid-Day Market Update: Crude Oil Up Over 1%; Cyclacel Pharma Shares Plummet - Benzinga www.benzinga.com - July 19 at 4:20 PM
	Pre-Market Most Active for Jul 19, 2017 : MT, VRTX, RAD, BFR, SNI, MS, BABA, SNY, TVIX, MU, QQQ, FB - Nasdaq www.nasdaq.com - July 19 at 4:20 PM
	US STOCKS-S&P, Nasdaq at records as Vertex rallies; IBM slips finance.yahoo.com - July 19 at 4:20 PM
	Why Vertex Pharmaceuticals Incorporated Stock Is Soaring Today www.fool.com - July 19 at 2:21 PM
	Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Downgraded to "Neutral" at UBS AG www.americanbankingnews.com - July 19 at 1:15 PM